Search results for "ABO"

showing 10 items of 13628 documents

Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐…

2020

Abstract Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on oral antihyperglycaemic drugs with an HbA1c of 9% or higher. Methods This retrospective cohort study assessed the impact of the timing of initiating both basal insulin and GLP‐1 RA therapies on reaching glycaemic targets (HbA1c < 7% and <8%, and ≥1% and ≥2% HbA1c reduction) over 12 months in people with markedly uncontrolled T2D (HbA1c ≥ 9%) on oral antihyperglycaemic drugs identified on the Optum Humedica database (electronic medical records; …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismInsulins030209 endocrinology & metabolismGlycemic ControlType 2 diabetes030204 cardiovascular system & hematologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyGLP‐1 analogueInternal medicinecohort studyInternal MedicineHumansHypoglycemic AgentsInsulinMedicinebasal insulinRetrospective StudiesGlycated Hemoglobindatabase researchbusiness.industryMedical recordHazard ratioRetrospective cohort studyOriginal Articlesmedicine.diseaseGlucagon-like peptide-1Confidence intervalglycaemic controlDiabetes Mellitus Type 2Pharmaceutical PreparationsCohortOriginal Articletype 2 diabetesbusinessCohort studyDiabetes, Obesity and Metabolism
researchProduct

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 D…

2020

Introduction: Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic effect of liraglutide in a real-world prospective study on patients with type 2 diabetes (T2DM). Methods: Sixty-two patients with T2DM (31 men, 31 women; mean age ± standard deviation 61 ± 9 years) naïve to incretin-based therapies were treated with liraglutide (1.2 mg/day) as add-on therapy to metformin (1500–3000 mg/day) for 4 months. Laboratory analyses included the assessment of lipoprotein subclass profile by gel electrophoresis (Lipopri…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismLipoproteinsIncretin030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineCardiovascular risk Carotid intima-media thickness Lipoproteins Liraglutide Small dense low-density lipoproteinsType 2 diabetesInternal medicineDiabetes mellitusInternal MedicinemedicineCarotid intima-media thicknessSmall dense low-density lipoproteinsOriginal ResearchLiraglutidebusiness.industryType 2 diabetesLiraglutidemedicine.diseaseCardiovascular riskMetforminEndocrinologyIntima-media thicknessbusinessBody mass indexLipoproteinmedicine.drug
researchProduct

Fasting-mimicking diet prevents high-fat diet effect on cardiometabolic risk and lifespan

2021

Diet-induced obesity is a major risk factor for metabolic syndrome, diabetes and cardiovascular disease. Here, we show that a 5-d fasting-mimicking diet (FMD), administered every 4 weeks for a period of 2 years, ameliorates the detrimental changes caused by consumption of a high-fat, high-calorie diet (HFCD) in female mice. We demonstrate that monthly FMD cycles inhibit HFCD-mediated obesity by reducing the accumulation of visceral and subcutaneous fat without causing loss of lean body mass. FMD cycles increase cardiac vascularity and function and resistance to cardiotoxins, prevent HFCD-dependent hyperglycaemia, hypercholesterolaemia and hyperleptinaemia and ameliorate impaired glucose and…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismLongevityDiet High-FatMiceVascularityMetabolic DiseasesPhysiology (medical)Internal medicineDiabetes mellitusKetogenesisInternal MedicineMedicineAnimalsRisk factorCardiometabolic Riskbusiness.industrySettore BIO/16 - Anatomia UmanaCell BiologyFastingmedicine.diseaseObesityEndocrinologyAgeingCardiovascular DiseasesLean body massFemaleMetabolic syndromemedicine.symptombusiness
researchProduct

Comment on: Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injecti…

2020

medicine.medical_specialtyEndocrinology Diabetes and MetabolismMEDLINEGermanEndocrinologyInsulin Infusion SystemsInternal medicineInternal MedicineMedicineHumansHypoglycemic AgentsInsulinRegistriesInsulin injectionAgedAged 80 and overType 1 diabetesbusiness.industrymedicine.diseaselanguage.human_languageSubcutaneous insulinDiabetes Mellitus Type 1AustrialanguagebusinessOlder peopleDiabetic medicine : a journal of the British Diabetic Association
researchProduct

Small, dense low-density-lipoproteins and the metabolic syndrome.

2006

Small, dense low-density-lipoproteins (LDL) are associated with increased risk for cardiovascular diseases and diabetes mellitus and a reduction in LDL size has been reported in patients with coronary and non-coronary forms of atherosclerosis. LDL size has been accepted as an important predictor of cardiovascular events and progression of coronary artery disease as well as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Small, dense LDL, with elevated triglyceride levels and low HDL-cholesterol concentrations, constitute the 'atherogenic lipoprotein phenotype (ALP)', a form of atherogenic dyslipidemia that is a feature of type …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismMyocardial InfarctionCoronary DiseaseType 2 diabetesmetabolic syndromeCoronary artery diseasechemistry.chemical_compoundEndocrinologyatherosclerosipreventionRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansParticle SizeRisk factorNational Cholesterol Education ProgramTriglycerideVascular diseasebusiness.industrydense LDLsmallAtherosclerosismedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2chemistrydiabeteCardiologylipids (amino acids peptides and proteins)Metabolic syndromebusiness
researchProduct

The assessment of vertebral fractures in elderly women with recent hip fractures: the BREAK Study

2012

This study aimed to evaluate the prevalence of vertebral fractures in elderly women with a recent hip fracture. The burden of vertebral fractures expressed by the Spinal Deformity Index (SDI) is more strictly associated with the trochanteric than the cervical localization of hip fracture and may influence short-term functional outcomes. INTRODUCTION: This study aimed to determine the prevalence and severity of vertebral fractures in elderly women with recent hip fracture and to assess whether the burden of vertebral fractures may be differently associated with trochanteric hip fractures with respect to cervical hip fractures. METHODS: We studied 689 Italian women aged 60 years or over with …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismOsteoporosisDentistryWalkingelderlySeverity of Illness Indexvertebral fracture; hip fracture; elderly; osteoporosis; burdenThoracic VertebraeburdenHip fractureInternal medicinemedicinePrevalenceHumansLife StyleSpinal deformity indexCervical fractureTrochanteric fractureAgedAged 80 and overHip fractureLumbar VertebraeCervical fracturebusiness.industryHip FracturesSettore MED/34 - Medicina Fisica E RiabilitativaMiddle Agedmedicine.diseaseosteoporosisRheumatologyRadiographyItalyOrthopedic surgerycervical fracutre hip fracture spinal deformity index trochanteric fracture vertebral fractureSpinal deformitySpinal FracturesFemaleVertebral fracturebusinessOsteoporotic Fractures
researchProduct

Effects of ovariectomy and steroid replacement on GABAA receptor binding in female rat brain.

1991

Abstract The specific binding of tritiated muscimol to γ-aminobutyric acid (GABA) receptor sites was studied in distinct brain areas of female rats during different endocrine states. In diestrous rats with intact ovaries the highest receptor densities were found in the cortex (10.24 pmol/mg protein) and the lowest concentrations in the mediobasal hypothalamus (3.29 pmol/mg protein). Four weeks after removal of the ovaries, the number of binding sites was enhanced up to 2.4-fold in all brain areas investigated: the preoptic brain area, mediobasal hypothalamus, corticomedial amygdala, and cerebral cortex. The affinity of the binding sites remained unchanged. Substitution of estradiol and prog…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismOvariectomyClinical BiochemistryBiologyIn Vitro TechniquesTritiumBiochemistrySynaptic Transmissionchemistry.chemical_compoundEndocrinologyInternal medicineCortex (anatomy)medicineAnimalsReceptorMolecular BiologyProgesteroneEstradiolGABAA receptorMuscimolBrainRats Inbred StrainsCell BiologyLuteinizing HormoneReceptors GABA-ARatsPreoptic areamedicine.anatomical_structureEndocrinologynervous systemMuscimolchemistryCerebral cortexMolecular MedicineGABAergicFemaleHormoneThe Journal of steroid biochemistry and molecular biology
researchProduct

Oxytocin reduces romantic rejection-induced pain in online speed-dating as revealed by decreased frontal-midline theta oscillations

2021

Abstract Background Romantic rejection is an emotionally distressful experience profoundly affecting life, possibly leading to mental illness or suicide. Oxytocin (OT) is a neuropeptide widely implicated in reducing physical pain and negative emotions; however, whether OT has an effect on reducing intense social pain (e.g., romantic rejection) remains unknown. Here, we tested the effect of OT on social pain and investigated its role in the outcome evaluation phase of social decision-making. Methods Electroencephalographic recordings were obtained between August 2nd and October 20th, 2020 in Shenzhen University from 61 healthy participants in a double-blind, placebo-controlled study with a b…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPainElectroencephalographyAudiologyOxytocinSomatosensory systemEndocrinologymedicineHumansAssociation (psychology)Biological PsychiatryAnterior cingulate cortexInternetmedicine.diagnostic_testSupplementary motor areaEndocrine and Autonomic Systemsbusiness.industryCourtshipBrainElectroencephalographyMental illnessmedicine.diseasePsychiatry and Mental healthDistressmedicine.anatomical_structureOxytocinRejection Psychologybusinessmedicine.drugPsychoneuroendocrinology
researchProduct

Ghrelin reduces hepatic mitochondrial fatty acid beta oxidation.

2007

Ghrelin is a 28-amino-acid peptide secreted during starvation by gastric cells. Ghrelin physiologically induces food intake and seems to alter lipid and glucid metabolism in several tissues such as adipose tissue and liver. Liver has a key position in lipid metabolism as it allows the metabolic orientation of fatty acids between oxidation and esterification. We investigated the effects of peripheral ghrelin administration on 2 crucial parameters of fatty acid oxidation: the levocarnitine (L-carnitine)-dependent entry of the fatty acids in the mitochondria and the mitochondrial fatty acid oxidation. Ghrelin was either given to rats prior to the hepatocyte preparation and culture or used to t…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPeptide HormonesMitochondria LiverLevocarnitineEndocrinologyInternal medicineCarnitinemedicineAnimalsCarnitineRats WistarBeta oxidationCells Culturedchemistry.chemical_classificationdigestive oral and skin physiologyFatty AcidsFatty acidLipid metabolismBiological TransportMetabolismLipid MetabolismGhrelinRatsEndocrinologymedicine.anatomical_structurechemistryBiochemistryHepatocyteGhrelinEnergy MetabolismOxidation-Reductionhormones hormone substitutes and hormone antagonistsmedicine.drugJournal of endocrinological investigation
researchProduct

Genetic and environmental aspect of polycystic ovary syndrome.

2004

Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome determined in most patients by the association of two main factors: hyperandrogenism and insulin resistance. These characters are probably independent of each other and seem to be inherited by several different mechanisms. In some patients homozygous gene alteration has been found but in most patients PCOS seems to be determined by the association of gene polymorphisms that are common in the general population but alone are unable to determine phenotypic consequences. Alteration of genes that regulate the initial steps of ovarian steroidogenesis is probably the main causal factor of hyperandrogenism. Insulin resistance may be the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationBiologyEatingEndocrinologyInsulin resistanceInternal medicineInsulin receptor substratemedicineHumansGenetic Predisposition to DiseaseObesityeducationGeneeducation.field_of_studyHyperandrogenismmedicine.diseaseObesityPhenotypePolycystic ovaryEndocrinologyFemaleInsulin ResistanceEnergy MetabolismHyperandrogenismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct